Skip to main content
Top
Published in: Medical Oncology 3/2011

01-09-2011 | Original paper

Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix

Authors: Yaxi Ma, Baizhou Li

Published in: Medical Oncology | Issue 3/2011

Login to get access

Abstract

To investigate the significance of PRL-3 expression in progression and metastasis of squamous cell carcinoma of the cervix (SCC). PRL-3 expression was detected by immunohistochemistry in 22 normal cervical epithelia, 30 moderate–severe dysplasia (CIN II-III) and 90 SCC cases. A total of 28 patients with SCC had lymph node metastasis, and PRL-3 expression of metastatic lymph node was detected. The association between PRL-3 expression and various clinical pathological variables in 90 patients with SCC was analyzed. Expression of PRL-3 in SCC was higher than that in normal and CINII-III, as well as higher in CINII-III than in normal (P < 0.05 in all instances). PRL-3 expression was significantly different between different tumor sizes, lymph-vascular space invasion status and lymph node metastasis status (P < 0.05 in all instances). PRL-3 expression in lymph node metastasis was significantly higher than that in primary SCC (P = 0.049). In lymph node metastasis, the frequency of staining in cytoplasm predominantly was higher than that in matched primary cancers (P = 0.001). PRL-3 may be involved in carcinogenesis of cervix and lymph node metastases of SCC and serves as an unfavorable prognostic factor in patients with SCC. PRL-3 localization in plasma may be related with cancer progress and metastasis.
Literature
1.
go back to reference Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 2005;4:1653–61. Review.PubMedCrossRef Stephens BJ, Han H, Gokhale V, Von Hoff DD. PRL phosphatases as potential molecular targets in cancer. Mol Cancer Ther. 2005;4:1653–61. Review.PubMedCrossRef
2.
go back to reference Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res. 2004;10:7318–28.PubMedCrossRef Kato H, Semba S, Miskad UA, Seo Y, Kasuga M, Yokozaki H. High expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer Res. 2004;10:7318–28.PubMedCrossRef
3.
go back to reference Molleví DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer. 2008;99:1718–25.PubMedCrossRef Molleví DG, Aytes A, Padullés L, Martínez-Iniesta M, Baixeras N, Salazar R, et al. PRL-3 is essentially overexpressed in primary colorectal tumours and associates with tumour aggressiveness. Br J Cancer. 2008;99:1718–25.PubMedCrossRef
4.
go back to reference Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology. 2004;71:176–84.PubMedCrossRef Miskad UA, Semba S, Kato H, Yokozaki H. Expression of PRL-3 phosphatase in human gastric carcinomas: close correlation with invasion and metastasis. Pathobiology. 2004;71:176–84.PubMedCrossRef
5.
go back to reference Wang Z, Cai SR, He YL, Zhan WH, Zhang CH, Wu H, et al. Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients. J Cancer Res Clin Oncol. 2009;135:1041–6.PubMedCrossRef Wang Z, Cai SR, He YL, Zhan WH, Zhang CH, Wu H, et al. Elevated PRL-3 expression was more frequently detected in the large primary gastric cancer and exhibits a poor prognostic impact on the patients. J Cancer Res Clin Oncol. 2009;135:1041–6.PubMedCrossRef
6.
go back to reference Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res. 2005;11:6835–9.PubMedCrossRef Polato F, Codegoni A, Fruscio R, Perego P, Mangioni C, Saha S, et al. PRL-3 phosphatase is implicated in ovarian cancer growth. Clin Cancer Res. 2005;11:6835–9.PubMedCrossRef
7.
go back to reference Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111:806–15.PubMedCrossRef Fagerli UM, Holt RU, Holien T, Vaatsveen TK, Zhan F, Egeberg KW, et al. Overexpression and involvement in migration by the metastasis-associated phosphatase PRL-3 in human myeloma cells. Blood. 2008;111:806–15.PubMedCrossRef
8.
go back to reference Radke I, Götte M, Kersting C, Mattsson B, Kiesel L, Wülfing P. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer. 2006;95:347–54.PubMedCrossRef Radke I, Götte M, Kersting C, Mattsson B, Kiesel L, Wülfing P. Expression and prognostic impact of the protein tyrosine phosphatases PRL-1, PRL-2, and PRL-3 in breast cancer. Br J Cancer. 2006;95:347–54.PubMedCrossRef
9.
go back to reference Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003;63:2716–22.PubMed Zeng Q, Dong JM, Guo K, Li J, Tan HX, Koh V, et al. PRL-3 and PRL-1 promote cell migration, invasion, and metastasis. Cancer Res. 2003;63:2716–22.PubMed
10.
go back to reference Lee SW, Kim YM, Kim MB, Kim DY, Kim JH, Nam JH, et al. Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay. Tohoku J Exp Med. 2009;219:277–82.PubMedCrossRef Lee SW, Kim YM, Kim MB, Kim DY, Kim JH, Nam JH, et al. Chemosensitivity of uterine cervical cancer demonstrated by the histoculture drug response assay. Tohoku J Exp Med. 2009;219:277–82.PubMedCrossRef
11.
go back to reference Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol Cancer. 2007;17:1194–204.PubMedCrossRef Hirte HW, Strychowsky JE, Oliver T, Fung-Kee-Fung M, Elit L, Oza AM. Chemotherapy for recurrent, metastatic, or persistent cervical cancer: a systematic review. Int J Gynecol Cancer. 2007;17:1194–204.PubMedCrossRef
12.
go back to reference Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–33.PubMedCrossRef Long HJ 3rd, Bundy BN, Grendys EC Jr, Benda JA, McMeekin DS, Sorosky J, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study. J Clin Oncol. 2005;23:4626–33.PubMedCrossRef
13.
go back to reference Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M. Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer. 2009. [Epub ahead of print]. Ooki A, Yamashita K, Kikuchi S, Sakuramoto S, Katada N, Watanabe M. Phosphatase of regenerating liver-3 as a convergent therapeutic target for lymph node metastasis in esophageal squamous cell carcinoma. Int J Cancer. 2009. [Epub ahead of print].
14.
go back to reference Liu YQ, Li HX, Lou X, Lei JY. Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma. Arch Pathol Lab Med. 2008;132:1307–12.PubMed Liu YQ, Li HX, Lou X, Lei JY. Expression of phosphatase of regenerating liver 1 and 3 mRNA in esophageal squamous cell carcinoma. Arch Pathol Lab Med. 2008;132:1307–12.PubMed
15.
go back to reference Raspagliesi F, Ditto A, Quattrone P, Solima E, Fontanelli R, Dousias V, et al. Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. Int J Gynecol Cancer. 2005;15:88–93.PubMedCrossRef Raspagliesi F, Ditto A, Quattrone P, Solima E, Fontanelli R, Dousias V, et al. Prognostic factors in microinvasive cervical squamous cell cancer: long-term results. Int J Gynecol Cancer. 2005;15:88–93.PubMedCrossRef
16.
go back to reference Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch. 2007;450:303–10.PubMedCrossRef Miskad UA, Semba S, Kato H, Matsukawa Y, Kodama Y, Mizuuchi E, et al. High PRL-3 expression in human gastric cancer is a marker of metastasis and grades of malignancies: an in situ hybridization study. Virchows Arch. 2007;450:303–10.PubMedCrossRef
17.
go back to reference Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res. 2003;9:5607–15.PubMed Bardelli A, Saha S, Sager JA, Romans KE, Xin B, Markowitz SD, et al. PRL-3 expression in metastatic cancers. Clin Cancer Res. 2003;9:5607–15.PubMed
18.
go back to reference Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, et al. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol. 2004;164:2039–54.PubMedCrossRef Wu X, Zeng H, Zhang X, Zhao Y, Sha H, Ge X, et al. Phosphatase of regenerating liver-3 promotes motility and metastasis of mouse melanoma cells. Am J Pathol. 2004;164:2039–54.PubMedCrossRef
19.
go back to reference Ming J, Liu N, Gu Y, Qiu X, Wang EH. PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology. 2009;41:118–26.PubMedCrossRef Ming J, Liu N, Gu Y, Qiu X, Wang EH. PRL-3 facilitates angiogenesis and metastasis by increasing ERK phosphorylation and up-regulating the levels and activities of Rho-A/C in lung cancer. Pathology. 2009;41:118–26.PubMedCrossRef
20.
go back to reference Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol. 2006;17:1517–22.PubMedCrossRef Wang L, Peng L, Dong B, Kong L, Meng L, Yan L, et al. Overexpression of phosphatase of regenerating liver-3 in breast cancer: association with a poor clinical outcome. Ann Oncol. 2006;17:1517–22.PubMedCrossRef
Metadata
Title
Expression of phosphatase of regenerating liver-3 in squamous cell carcinoma of the cervix
Authors
Yaxi Ma
Baizhou Li
Publication date
01-09-2011
Publisher
Springer US
Published in
Medical Oncology / Issue 3/2011
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9514-3

Other articles of this Issue 3/2011

Medical Oncology 3/2011 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine